secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001140361-24-028205
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed prices $650M stock offering of 12.6M shares; net ~$713.9M
----------------------------------------------------------------

- Offering of 12,621,359 shares at $51.50/share; net proceeds to Insmed of ~$713.9M (incl. option exercise).
- Underwriters exercised full 30-day option to purchase an additional 1,893,203 shares.
- Proceeds to fund brensocatib R&D and pre-commercialization, ARIKAYCE commercialization, TPIP R&D.
- Goldman Sachs, Leerink Partners, and J.P. Morgan are joint book-running managers; Morgan Stanley, Cantor, Stifel co-lead.
- Offering expected to close May 31, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/0001140361-24-028205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/ny20029730x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-028205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer